Validation Data Gallery
Tested Applications
| Positive WB detected in | HeLa cells, HepG2 cells |
| Positive IF/ICC detected in | HepG2 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:500-1:1000 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:200-1:800 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| WB | See 3 publications below |
| IHC | See 1 publications below |
| IF | See 1 publications below |
Product Information
20865-1-AP targets TFPI in WB, IHC, IF/ICC, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen | TFPI fusion protein Ag14913 相同性解析による交差性が予測される生物種 |
| Full Name | tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) |
| Calculated molecular weight | 251aa,29 kDa; 304aa,35 kDa |
| Observed molecular weight | 40-45 kDa |
| GenBank accession number | BC015514 |
| Gene Symbol | TFPI |
| Gene ID (NCBI) | 7035 |
| RRID | AB_10693682 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | P10646 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol , pH 7.3 |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
Tissue factor pathway inhibitor (TFPI) is a critical anticoagulant protein present in endothelium and platelets. TFPI is produced as two major isoforms in humans, TFPIa and TFPIb that result from alternative splicing. The TFPIb isoform localizes to the endothelium surface where it is a potent inhibitor of tissue factor-factor VIIa complexes that initiate blood coagulation. The TFPIa isoform is present in platelets. TFPI is a Kunitz-type serine protease inhibitor that exerts anticoagulant activity by blocking early procoagulant stimulia. TFPI can enhance anti-thrombotic treatment in sepsis, inflammatory diseases, and cardiovascular diseases.
Protocols
| Product Specific Protocols | |
|---|---|
| WB protocol for TFPI antibody 20865-1-AP | Download protocol |
| IF protocol for TFPI antibody 20865-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Gene ADTRP regulates TFPI expression via transcription factor POU1F1 involved in coronary artery disease. | ||
Clin Appl Thromb Hemost Endocardial Changes in Nonvalvular Atrial Fibrillation Without Atrial Thrombus-Thrombomodulin and Tissue Factor Pathway Inhibitor. | ||
Thromb Res Activated protein C, protein S, and tissue factor pathway inhibitor cooperate to inhibit thrombin activation | ||
Drug Resist Updat YTHDF2-mediated m6A modification of ONECUT2 promotes stemness and oxaliplatin resistance in gastric cancer through transcriptionally activating TFPI |